Raphael Pharmaceutical (RAPH) Return on Capital Employed (2021 - 2024)

Raphael Pharmaceutical (RAPH) has 4 years of Return on Capital Employed data on file, last reported at 206.71% in Q4 2024.

• For the quarter ending Q4 2024, Return on Capital Employed rose 87973.0% year-over-year to 206.71%; the trailing twelve-month figure through Dec 2024 stood at 206.71% (up 87973.0% YoY), and the FY2025 full-year result was 86.1%, down 15116.0% from the prior year.
• Return on Capital Employed rose to 206.71% in Q4 2024, from 169.87% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 11375.51% in Q3 2022 to a low of 4121.21% in Q1 2023.
• A 4-year average of 1478.73% and a median of 495.19% in 2024 frame the typical range for Return on Capital Employed.
• Peak annual rise in Return on Capital Employed reached 866562 bps in 2023, while the deepest fall reached 1021883 bps in 2023.
• Tracing RAPH's Return on Capital Employed over 4 years: stood at 3132.69% in 2021, then jumped by 263 bps to 11375.51% in 2022, then sank by 106 bps to 673.02% in 2023, then soared by 131 bps to 206.71% in 2024.
• Business Quant data shows RAPH's Return on Capital Employed at 206.71% in Q4 2024, 169.87% in Q3 2024, and 783.66% in Q2 2024.